InterCure Ltd.

As of June 30, 2023, InterCure Ltd. carries a market capitalization of 28.26B, placing it among publicly traded companies globally. Its enterprise value stands at 36.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2023, InterCure Ltd. has 9.11M shares outstanding.

As of June 30, 2023, InterCure Ltd. trades at a trailing price-to-earnings ratio of 13.29. The price-to-sales ratio is 0.67, and the price-to-book ratio stands at 0.56.

As of June 30, 2023, InterCure Ltd. trades at an EV/EBITDA multiple of 10.41 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.76 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 36.14B versus a market cap of 28.26B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2023, InterCure Ltd. maintains a current ratio of 1.90, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 30.86, indicating elevated leverage, while an interest coverage ratio of 1.70 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2023, InterCure Ltd. posted a return on equity (ROE) of 4.23, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 2.56, measuring how efficiently the asset base is converted into earnings. The company generates approximately 414.79M in revenue per employee across its workforce of 100.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.28 indicates how many times InterCure Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2023, InterCure Ltd. recorded an income tax benefit of -1.20B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 539.90M, leaving 2.09B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, InterCure Ltd.'s stock has declined approximately 42.05% over the past 52 weeks. The 50-day moving average sits at 1,572.74, while the 200-day moving average is 1,445.16.

Over the twelve months ended June 30, 2023, InterCure Ltd. generated 41.48B in revenue and converted that into 2.09B in net income, yielding earnings per share of 193.99. EBITDA reached 3.47B, while operating income came in at 1.67B.

As of June 30, 2023, InterCure Ltd. holds 10.28B in cash and equivalents against 16.28B in total debt, resulting in a net debt position of 3.89B. Total book value stands at 50.88B, with working capital of 18.68B providing operational flexibility.

These figures cover the twelve months ended June 30, 2023.

Over the twelve months ended June 30, 2023, InterCure Ltd. posted a gross margin of 33.52, reflecting its pricing power and cost economics. The operating margin of 4.04 and net profit margin of 5.04 provide insight into operational efficiency.

InterCure Ltd.'s most recent stock split took place on August 24, 2026 with a 5:1 split ratio.

As of June 30, 2023, InterCure Ltd. has an Altman Z-Score of 1.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.